Gene · 10683
Papers2,335
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,335
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies. | Discov Oncol | 2025 | 40956459 | PubTator, text mining | PubMed |
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. | Lancet Oncol | 2025 | 40934933 | PubTator, text mining | PubMed |
| Tarlatamab Exposure-Efficacy and Exposure-Safety Relationships to Inform Dose Selection in Patients with Small Cell Lung Cancer. | Clin Cancer Res | 2025 | 40928991 | PubTator, text mining | PubMed |
Comprehensive Analysis of Neurogenic Differentiation Factor 1 (NEUROD1), Achaete-Scute Homolog 1 (ASCL1), POU Class 2 Homeobox 3 (POU2F3), and Yes-Associated Protein 1 (YAP1) Expression Signatures Reveals Unique Large-Cell Neuroendocrine Carcinoma (LCNEC) Subgroups With Potential Therapeutic Implications. | Lab Invest | 2025 | 40902984 | PubTator, text mining | PubMed |
| Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer. | Cancer Heterog Plast | 2025 | 40893664 | PubTator, text mining | PubMed |
| Small cell lung cancer (SCLC): At the door of targeted therapies. | Biomol Biomed | 2025 | 40884462 | PubTator, text mining | PubMed |
| Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer. | Lung Cancer | 2025 | 40865373 | PubTator, text mining | PubMed |
| Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances. | J Exp Clin Cancer Res | 2025 | 40849493 | PubTator, text mining | PubMed |
| Cytokine release syndrome in solid tumors. | Cancer | 2025 | 40847830 | PubTator, text mining | PubMed |
| Persistent lineage plasticity driving lung cancer development and progression. | Clin Transl Med | 2025 | 40847555 | PubTator, text mining | PubMed |
| Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer. | Med Sci (Basel) | 2025 | 40843764 | PubTator, text mining | PubMed |
| Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. | Nat Commun | 2025 | 40830141 | PubTator, text mining | PubMed |
| CircRNAs: functions and emerging roles in cancer and immunotherapy. | BMC Med | 2025 | 40817061 | PubTator, text mining | PubMed |
| Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches. | Biochim Biophys Acta Rev Cancer | 2025 | 40784437 | PubTator, text mining | PubMed |
| The novel role of Kallistatin in linking metabolic syndromes and cognitive memory deterioration by inducing amyloid-β plaques accumulation and tau protein hyperphosphorylation. | Elife | 2025 | 40762561 | PubTator, text mining | PubMed |
| Beyond linear: How circRNAs twist and turn Notch signaling. | J Cell Commun Signal | 2025 | 40761890 | PubTator, text mining | PubMed |
| A Case of Micro-medullary Thyroid Carcinoma Presenting as Cancer of Unknown Primary. | Cureus | 2025 | 40747199 | PubTator, text mining | PubMed |
| New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic. | Research (Wash D C) | 2025 | 40746825 | PubTator, text mining | PubMed |
| Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. | Signal Transduct Target Ther | 2025 | 40739089 | PubTator, text mining | PubMed |
| Advances in the diagnosis and treatment of congenital scoliosis. | Eur J Med Res | 2025 | 40731016 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10683/papers?page=10